A Public Health Crisis
======================

"What do you do when you're faced with an infection, with a very sick patient, and you get a lab report back and every single drug is listed as resistant?" asked Dr. Fred Tenover of Center for Disease Control and Prevention (CDC). "This is a major blooming public health crisis."

A Glimpse of the Resistance History
===================================

Bacterial resistance is not a new phenomenon in our society. Since the beginning of antibiotic usage in therapeutics medicine, the health care system is being challenged by this problematic ([@b3-bjm-45-1]; [@b29-bjm-45-1]). It does not represent only one field disaster; it involves a diverse group of sectors: political, economical, biological, social and ecological with unknown outcomes and no immediate solution.

The appearance of penicillin resistance occurred in the 40's, just after the large scale antibiotic usage and while doctors, pharmacists and microbiologists accompanied the rise of the resistance until the mid 80's the global picture started to be treated as a permanent and rising problem and as a threat to the Public Health system ([@b7-bjm-45-1]; [@b29-bjm-45-1]; [@b30-bjm-45-1]).

The history of bacterial infectious diseases can be divided in three eras: the pre-antibiotic era, the antibiotics era and the antibiotic resistance emergence era. The emergence of resistance in the current world created a risky, but necessary situation regarding the patient treatment, because when facing a bacterial infection the most powerful antibiotics classes are preserved as last resource in therapy, although bacteria already possess mechanisms of making these classes ineffective ([@b10-bjm-45-1]; [@b26-bjm-45-1]). Therefore, in the last decade the changes in the susceptibility scenario had a drastic impact in the therapeutic options in treating community-acquired and hospital-acquired infections ([@b23-bjm-45-1]; [@b28-bjm-45-1]).

The return to the pre-antibiotic era is becoming an imminent reality in many parts of the world ([@b8-bjm-45-1]; [@b27-bjm-45-1]), making evident that we are entering an era where the gains that the antibiotics will bring will be minimal, therefore it has never been more important to know the details of mechanisms and the routes of resistance so that therapies, practices, surveillance and research can be adjusted, minimizing the increase of resistance in the future.

The increasing prevalence of resistant and multi-resistant bacterial strains has become a serious problem to health care systems all over the world ([@b12-bjm-45-1]; [@b19-bjm-45-1]). From the economical point of view, infections caused by multi-resistant organisms are a constant concern, because its therapeutic management represents a substantial increase of costs for the health system. The economic impact of antimicrobial choices in multi-resistant infections is an increasing problem since a number of researches document the huge extra cost in the health care system, highlighting the caution in the antibiotic prescriptions and the search for information on old and new drugs and on their efficacy ([@b31-bjm-45-1]).

Every new antibiotic class that arises is followed by the emergence of resistance to this and other classes, leaving patients vulnerable to infections that are not treatable by any of the available antibiotics. Even the newest antimicrobial classes, with a broad spectrum activity, are already being associated to the decrease in susceptibility levels ([@b15-bjm-45-1]; [@b24-bjm-45-1]).

It is known that the group of multi-resistant bacteria usually causes more damage to the infected patients when compared to those outcomes of patients afflicted by susceptible strains from the same species. This data can be seen in infections caused by bacteria such as *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Enterobacter*, and others. The reason for such unsatisfactory results is not necessarily linked to the virulence profile of the strain, but to the antimicrobial empiric treatment that was given to these patients in the beginning of the infection ([@b14-bjm-45-1]).

The Antibiotics *vs.* Bacteria Race
===================================

Every time a drug is prescribed to a patient, all bacteria whether is the target of infection or not are reached, causing a survival pressure over these bacteria, leading to the rise of antimicrobial resistance, which is an evolutionary process characterized by the competition between the resistant and sensitive strains. These processes can occur, individually; in patients, asymptomatic populations or in the environment ([@b30-bjm-45-1]).

The world accompanies bacterial adaptation against old and new launched drugs, and repetitively we experience crises that affect the government, hospitals committees, pharmaceutical companies, researchers and the population, which frequently return to the square one in protocols and antimicrobial therapy councils.

Despite the efforts to improve antibiotics, bacteria continue to evolve in response to the drugs they are exposed to, and in many cases the organisms present in the environment already possess resistance to antimicrobials there are still in the approval process by FDA (Food and Drug Administration) ([@b4-bjm-45-1]).

The reasons for antimicrobial resistance increase are complex, but through the studies it has become evident that the excessive use of antibiotic is linked to the selection and emergence of resistance. This increase and spread can also be associated to the host population structure, which mainly occurs due to the interaction of the hospital and community ([@b13-bjm-45-1]; [@b15-bjm-45-1]).

Several infection control measures, aiming public health and improvement of life quality were described over the years. Worldwide campaigns are being launched to fight, remedy or minimize the damages caused by resistant and multi-resistant bacteria, but these interventions require a balance between the individual right and the population protection.

Surprisingly, despite the dogma created a few years ago, the increase and spread of resistance is not caused or restrict only to hospitals and the excessive use of antibiotics. The presence of resistant bacteria strains in sewage, water, food, soil and others, demonstrates the participation of environmental pressure on these strains, and by associating these data with the presence of antibiotics in the environment, its use in veterinarian therapy and agriculture, researches from all over the world are expanding their studies outside the hospitals.

An Unexpected, but Induced Enemy
================================

It is estimated that approximately 5×10^30^ bacteria cells exist in the planet, most not pathogenic organisms. These bacteria interact with a variety of chemical substances in the environment, produced by other bacteria, fungi, plants, animals or by man itself ([@b32-bjm-45-1]; [@b33-bjm-45-1]). Considering the environmental problems caused by these chemicals, dissemination, persistence and emergence of resistant bacteria are directly associated. The increase in the evidences that correlate the clinical and environmental resistance highlights that information and researches in this field must be expanded, including pathogenic and non-pathogenic microorganisms.

The genetic adaptability gives bacteria a huge advantage over mankind. A polluted and anthropologically affected environment withholds a resistance reservoir, where a diverse of bacteria species and even genus; maintain, develop and exchange genetic determinants that constitute a risk to human and ecological health.

Studies have been searching for the presence of resistance genes in bacteria isolated from non-clinical sources, such as food, water, soil, sewage and others. However, the role of the environment in the origin and transmission of resistance is a theme that requires more investigation ([@b1-bjm-45-1]; [@b2-bjm-45-1]; [@b6-bjm-45-1]; [@b17-bjm-45-1]; [@b18-bjm-45-1]; [@b22-bjm-45-1]).

Our background experience also indicates that temporal researches are important in elucidating the environment involvement in bacteria resistance. Culture collections from different period of time are an important source of information when combined with new data. Genotypic and phenotypic changes can be detected in these collections, which also results in a timeline data interpretation of distribution, persistence, dissemination and mobility of important antibiotic resistance markers.

Most resistance genes are acquired by horizontal transfer of genetic mobile elements, harmless in the beginning. However, they have consequently followed the uncontrolled use of antibiotics and became vectors of antimicrobial resistance. Despite the absence of direct information, it is speculated that the origin of these resistance genes is the environmental resistome ([@b2-bjm-45-1]; [@b6-bjm-45-1]; [@b31-bjm-45-1]).

Antibiotic Resistance: Social, Economical and Biological Aspects
================================================================

The history of efforts to control infectious pathogens shows a concerning fact: as the antimicrobials were use by long periods, the bacteria resistance evolved. This resistance has substantially decreased our ability in controlling several important diseases, leading not only to economic losses, but also to social damages in the Public Health field ([@b19-bjm-45-1]; [@b30-bjm-45-1]).

The bacteria resistance, a worldwide process that has known a rapid and uncontrolled growth in the last two decades, is nowadays accepted as one of the major public health problems. It manifests the increase of infection or the prolonged clinical symptomatology, increase in hospital stay, and not less important, the rise of costs to the health system ([@b5-bjm-45-1]; [@b7-bjm-45-1]; [@b12-bjm-45-1]; [@b13-bjm-45-1]; [@b16-bjm-45-1]; [@b28-bjm-45-1]; [@b31-bjm-45-1]).

It is known that infectious diseases characterized by their specific signs and symptoms, as cholera and influenza, have reached different places in different times. During the last century the microbiology field has also shown the occurrence of less evident infectious diseases through laboratories that can identify the microorganisms associated with the diseases. Since the emergence of resistant bacteria has reached a critical condition, a new task has arise to microbiologists: starting testing *in vitro* bacteria resistance of strains isolated from patients, aiming to report which agents could still be used to cure that patients. Genes expressing resistance to different agents eventually emerged under pressure, spread to several bacteria species, and combine themselves to create totally untreatable strains until the development of a new drug ([@b12-bjm-45-1]; [@b20-bjm-45-1]).

The emergence and spread of bacteria resistance can be associated with many factors, but they always represent an evolution process: a response to selective pressure. The impact of this resistance can be substantial or insignificant, depending on the level of resistance, the infection site and the availability of effective therapies ([@b14-bjm-45-1]; [@b23-bjm-45-1]).

The emergence and dissemination of Gram-negative bacteria are associated to serious public health issues, which implicate in a continuous and update monitoring ([@b8-bjm-45-1]; [@b9-bjm-45-1]; [@b11-bjm-45-1]; [@b26-bjm-45-1]; [@b27-bjm-45-1]). This concern can be detected in the current generation, which collects, groups and analyses all the information involving nature, dissemination and distribution of microorganisms and their resistance to antibiotics, aiming the improvement of life quality.

The bacteria resistance combat must be led by biologic scientists, although social researches play an important role in the behavior aspects of the problem. Both, patients and health professionals, should be aware that the increase in bacteria resistance is in part caused by inappropriate behavior in many factors, such as follow-up of medical therapy by the patient, self-medication, drug prescription, hand-washing in medical procedures, and others ([@b7-bjm-45-1]; [@b13-bjm-45-1]; [@b25-bjm-45-1]).

In What Can Our Future Rely On?
===============================

The resistance to the available antibiotics is increasing in an alarming level. At the same time, the development of new antimicrobial agents is decreasing. With the emergence and dissemination of the resistance and the appearance of new bacterial pathogens, the urgency for the discovery of new drugs should be treated as a priority, associated with the new discoveries, surveillance and controlling programs, although the pharmaceuticals companies have decreased the development of new antibiotics ([@b4-bjm-45-1]; [@b12-bjm-45-1]; [@b21-bjm-45-1]).

During the past decade the efforts to combat multi-resistant microorganisms were mainly focused in Gram-positive bacteria and the pharmaceutical companies have developed new drugs to fight these organisms. Unfortunately, the growing problem of Gram-negative resistance was not parallel to the discovery of antibiotics to treat infections caused by these bacteria, resulting in a substantial number of untreatable infections and in the emergence of a disturbing perspective ([@b27-bjm-45-1]).

A Hopeful Conclusion
====================

Every time our world faces a predictable, but inevitable tragic outcome, the first reaction is to join forces, to bring together all the information, knowledge and tools aiming the same result: the establishment of balance.

Doctors, microbiologists, pharmacists, pharmaceutical CEO's, researchers and the general public must share all the available data on antimicrobials, infections, therapy and public health threat of resistance. They must also engage their best efforts to follow the management therapies, programs and bacteria resistance councils.

Numerical reports are important, but in the midst of information apparently we are lacking experience reports, because with so many data, so many achievements, minor details get lost, and those are the ones that remain a question mark in geographically distant, but so close related laboratories. Minor results, difficulties, observations, chemicals, phenotypic and genotypic changes, and so many others, are as important and crucial as the numerical data, and unfortunately their exchange is being left behind by so many researchers and physicians.

From the public health point of view the antimicrobial resistance is a problem that requires campaigns mainly associated with health care professionals, but also a language that can reach the general public. In order to verify the economic impact on health care systems, an integrate council, formed by administrators, doctors, researches and economists should bring data from all the sectors involved aiming to discuss the best proposal treatment in common cases of infections, so that can reflect positively on the general budget distribution that reaches other sectors inside the health care systems.

Surveillance is a crucial factor in creating a path to reach the effects caused by resistance. Although surveillance exists worldwide, an integration of data is desperately needed, because many researchers are thinking regional, others national, but the aim is to think global not only in numerical data. International projects with multi-professional participants already exist, but the creation of other programs should continue and the ones that exist should comprise professionals from economic, administrative and social fields.

The threat of multi-resistant bacteria is a critical public health issue that requires a coordinated and multifaceted response, not excluding veterinarians, agriculturalists and media representatives. Feeding the webs of integrated information with the available data from all the participants fields we can minimize selective pressure, overcome the problems in new drugs development, implement a working management therapy, redirect the extra costs to an alternative supporting resistance program, so that in the future we may be able to maintain antimicrobial susceptibility patterns at a level we can live with.

All the proposals herein discussed, and others existent in so many studies are not impossible to achieve, because great minds inhabit our world and put together they can definitely be greater.
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